Abeona Therapeutics Inc (ABEO)

Currency in USD
7.0000
-0.0200(-0.28%)
Closed·
7.0100+0.0100(+0.14%)
·
ABEO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.87007.1650
52 wk Range
4.00007.5401
Key Statistics
Prev. Close
7.02
Open
6.9
Day's Range
6.87-7.165
52 wk Range
4-7.5401
Volume
777.46K
Average Volume (3m)
1.2M
1-Year Change
6.2215%
Book Value / Share
2.54
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABEO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
19.7143
Upside
+181.63%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Abeona Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 19.7143
(+181.63% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Oppenheimer
Buy22.00+214.29%-MaintainMar 17, 2026
Stifel
Buy17.00+142.86%19.00MaintainMar 17, 2026
Oppenheimer
Buy22.00+214.29%19.00MaintainMar 09, 2026
Cantor Fitzgerald
Buy28.00+300.00%-MaintainJan 15, 2026
Stifel
Buy19.00+171.43%20.00MaintainNov 12, 2025

Abeona Therapeutics Inc Earnings Call Summary for Q1/2026

  • Abeona Therapeutics Q1 2026 revenue hit $8.72M, beating forecast by 88.74%; EPS of -$0.30 topped estimate of -$0.34 by 11.76%
  • Revenue surged 262% quarter-over-quarter driven by three commercially insured patients at $2.9M average per patient for ZEVASKYN
  • Stock declined 3.1% in premarket despite earnings beat; SG&A expenses jumped 42.5% YoY with Q1 cash burn reaching $23.1M
  • Company maintains guidance for potential monthly profitability starting June 2026; projects revenue growth to $27.5M by Q2 2027
  • Gross margin reached 69% with $6M profit, but analysts expect full-year 2026 EPS of -$0.83 as profitability remains elusive
Last Updated: 2026-05-18, 07:24 a/m
Read Full Transcript

Earnings

Latest Release
May 13, 2026
EPS / Forecast
-0.30 / -0.34
Revenue / Forecast
8.72M / 4.62M
EPS Revisions
Last 90 days

ABEO Income Statement

Compare ABEO to Peers and Sector

Metrics to compare
ABEO
Peers
Sector
Relationship
P/E Ratio
6.0x5.5x−0.4x
PEG Ratio
0.03−0.130.00
Price/Book
2.8x2.0x2.6x
Price / LTM Sales
27.4x11.2x3.0x
Upside (Analyst Target)
185.7%172.9%50.8%
Fair Value Upside
Unlock11.8%9.4%Unlock

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Employees
226

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
7.22M12.68%50.57M
Other Institutional Investors
37.41M65.64%261.88M
Public Companies & Retail Investors
12.36M21.68%86.51M
Total
57M100.00%398.97M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Nantahala Capital Management, LLC8.80%5,013,05235,091
Nantahala Capital Partners Limited Partnership5.85%3,333,75723,336

People Also Watch

54.39
IONS
-0.48%
267.47
ALNY
-5.54%
0.665
HUMA
+0.76%
2.830
CABA
+5.99%
6.270
ACHV
+5.20%

FAQ

What Is the Abeona Therapeutics (ABEO) Stock Price Today?

The Abeona Therapeutics stock price today is 7.0000 USD.

What Stock Exchange Does Abeona Therapeutics Trade On?

Abeona Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Abeona Therapeutics?

The stock symbol for Abeona Therapeutics is "ABEO."

What Is the Abeona Therapeutics Market Cap?

As of today, Abeona Therapeutics market cap is 398.9700M USD.

What Is Abeona Therapeutics's Earnings Per Share (TTM)?

The Abeona Therapeutics EPS (TTM) is 0.9143.

When Is the Next Abeona Therapeutics Earnings Date?

Abeona Therapeutics will release its next earnings report on Aug 12, 2026.

From a Technical Analysis Perspective, Is ABEO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Abeona Therapeutics Stock Split?

Abeona Therapeutics has split 4 times.

How Many Employees Does Abeona Therapeutics Have?

Abeona Therapeutics has 226 employees.

What is the current trading status of Abeona Therapeutics (ABEO)?

As of Jul 18, 2026, Abeona Therapeutics (ABEO) is trading at a price of 7.0000 USD, with a previous close of 7.0200 USD. The stock has fluctuated within a day range of 6.8700 USD to 7.1650 USD, while its 52-week range spans from 4.0000 USD to 7.5401 USD.

What Is Abeona Therapeutics (ABEO) Price Target According to Analysts?

The average 12-month price target for Abeona Therapeutics is 19.7143 USD, with a high estimate of 28 USD and a low estimate of 14 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +181.63% Upside potential.

What Is the ABEO Premarket Price?

ABEO's last pre-market stock price is 6.9600 USD. The pre-market share volume is 64,720.0000, and the stock has decreased by -0.0600, or -0.8500%.

What Is the ABEO After Hours Price?

ABEO's last after hours stock price is 7.0100 USD, the stock has decreased by 0.0100, or 0.1400%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.